Vergelijking
Cagrilintide vs. Eloralintide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
1415456-99-3
geen gegevens
Molecuulmassa
4253.7 g/mol
geen gegevens
Halfwaardetijd
168 h
geen gegevens
Sequentie
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYgeen gegevens
Werkingsmechanisme
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
2
waarvan bij mensen
3
1
Geregistreerde effecten
3
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Cagrilintide and Eloralintide?
- Cagrilintide is classified as "Metabool", while Eloralintide is classified as "Metabool". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Eloralintide?
- The highest available evidence level is "Humane RCT" for Cagrilintide and "Humane RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Eloralintide in Germany and the United States?
- Duitsland: Cagrilintide — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. Verenigde Staten: Cagrilintide — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.